OBJECTIVES: This study reports the initial clinical and echocardiographic results of the Premium bioprosthetic aortic valve up to 4 years of follow-up. METHODS: Between October 2007 and July 2011, 121 consecutive patients were submitted for aortic valve replacement with the Premium bioprosthetic valve. The mean age was 68 ± 9 years and 64 patients were males. The patients were periodically evaluated by clinical and echocardiographic examinations. The mean follow-up was 21 months (min = 2, max = 48), yielding 217 patients/year for the analysis. RESULTS: The hospital mortality was 8%. Late survival at 3 years was 89% (95% CI: 81.9-93.3%), and 80% of the patients were in NYHA functional class I/II. The rates of valve-related complications were low, with a linearized incidence of 0.9%/100 patients/year for thromboembolic complications, 0% for haemorrhagic events and 0.9%/100 patients/year of bacterial endocarditis. There was no case of primary structural valve dysfunction. The mean effective orifice area was 1.61 ± 0.45 cm(2); mean gradient 13 ± 5 mmHg and peak gradient 22 ± 9 mmHg. Significant patient-prosthesis mismatch was found in only 11% of the cases. CONCLUSIONS: The Premium bioprosthetic aortic valve demonstrated very satisfactory clinical and echocardiographic results up to 4 years, similar to other commercially available, third-generation bioprosthetic valves.
OBJECTIVES: This study reports the initial clinical and echocardiographic results of the Premium bioprosthetic aortic valve up to 4 years of follow-up. METHODS: Between October 2007 and July 2011, 121 consecutive patients were submitted for aortic valve replacement with the Premium bioprosthetic valve. The mean age was 68 ± 9 years and 64 patients were males. The patients were periodically evaluated by clinical and echocardiographic examinations. The mean follow-up was 21 months (min = 2, max = 48), yielding 217 patients/year for the analysis. RESULTS: The hospital mortality was 8%. Late survival at 3 years was 89% (95% CI: 81.9-93.3%), and 80% of the patients were in NYHA functional class I/II. The rates of valve-related complications were low, with a linearized incidence of 0.9%/100 patients/year for thromboembolic complications, 0% for haemorrhagic events and 0.9%/100 patients/year of bacterial endocarditis. There was no case of primary structural valve dysfunction. The mean effective orifice area was 1.61 ± 0.45 cm(2); mean gradient 13 ± 5 mmHg and peak gradient 22 ± 9 mmHg. Significant patient-prosthesis mismatch was found in only 11% of the cases. CONCLUSIONS: The Premium bioprosthetic aortic valve demonstrated very satisfactory clinical and echocardiographic results up to 4 years, similar to other commercially available, third-generation bioprosthetic valves.
Authors: K Hammermeister; G K Sethi; W G Henderson; F L Grover; C Oprian; S H Rahimtoola Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: W R Eric Jamieson; Clifton T P Lewis; Marc P Sakwa; Denton A Cooley; Vibhu R Kshettry; Kent W Jones; Tirone E David; John A Sullivan; Guy J Fradet; David S Bach Journal: J Thorac Cardiovasc Surg Date: 2011-02-01 Impact factor: 5.209
Authors: María José Dalmau; José Maríagonzález-Santos; Javier López-Rodríguez; Maria Bueno; Antonio Arribas Journal: Interact Cardiovasc Thorac Surg Date: 2006-02-20
Authors: John P A Puvimanasinghe; Johanna J M Takkenberg; Marinus J C Eijkemans; Lex A van Herwerden; W R Eric Jamieson; Gary L Grunkemeier; J Dik F Habbema; Ad J J C Bogers Journal: Eur J Cardiothorac Surg Date: 2006-01-18 Impact factor: 4.191
Authors: Andrea Dumsch de Aragon Ferreira; Francisco Diniz Affonso da Costa; Eduardo Antonio Andrade dos Santos; Evandro Antonio Sardeto; Carlos Henrique Gori Gomes; Claudinei Collatusso; Sérgio Augusto Veiga Lopes; Angela Perruzzo; Iseu de Santo Elias Affonso da Costa Journal: Rev Bras Cir Cardiovasc Date: 2007 Jul-Sep
Authors: James M Brown; Sean M O'Brien; Changfu Wu; Jo Ann H Sikora; Bartley P Griffith; James S Gammie Journal: J Thorac Cardiovasc Surg Date: 2009-01 Impact factor: 5.209
Authors: Lisandro Gonçalves Azeredo; Elinthon Tavares Veronese; José Augusto Duncan Santiago; Carlos Manuel de Almeida Brandão; Pablo Maria Alberto Pomerantzeff; Fabio Biscegli Jatene Journal: Rev Bras Cir Cardiovasc Date: 2014 Jul-Sep